Nivolumab (regardless of PD-L1 expression status) [56] and pembrolizumab (PD-L1 CPS ≥ 10) [57] improved OS when prospectively compared to the investigator’s choice in pretreated advanced esophageal squamous cell carcinoma. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.